PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Program of Immunology and Immunotherapy, Cima Universidad De Navarra, Pamplona, Spain.\', \'Navarra Institute for Health Research (Idisna), Pamplona, Spain.\', \'Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, The Netherlands.\', \'Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh UK.\', \'Centro De Investigación Biomédica En Red De Cáncer (Ciberonc), Spain.\', \'Departments of Oncology and Immunology, Clínica Universidad De Navarra, Pamplona, Spain.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/17460441.2021.1978972
?:doi
?:hasPublicationType
?:journal
  • Expert opinion on drug discovery
is ?:pmid of
?:pmid
?:pmid
  • 34496689
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.309
?:rankingScore_hIndex
  • 46
?:title
  • Advances in mRNA-based drug discovery in cancer immunotherapy.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34496689>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34496689>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all